Past, present and future of gene expression-tailored therapy for lung cancer

Personalized Medicine

Volumn 3, Issue 2, 2006, Pages 165-175

  Marrer, Estelle ^a   Baty, Florent ^b   Kehren, Jeanne ^a   Chibout, Salah Dine ^a   Brutsche, Martin ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarkers; Classification; Diagnosis; Genomics; Lung cancer; Personalized medicine; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR INHIBITOR; IMATINIB; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ALGORITHM; CANCER CLASSIFICATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; DRUG UTILIZATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVIEW; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; VALIDATION PROCESS;

EID: 33646794441     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.2.165     Document Type: Review

References (65)

1. American Cancer Society: Cancer facts and figures 2005. American Cancer Society, Atlanta, GA, USA (2005).
2. Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346(2), 92-98 [Clinical Trial] (2002).
3. Klastersky J, Paesmans M: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 34(Suppl. 4), 95-101 (2001).
4. Meyerson M, Carbone D: Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J. Clin. Oncol. 23 (14), 3219-3226 (2005).
5. Mariani TJ, Kaminski N: Gene expression studies in lung development and lung stem cell biology. Curr. Top. Dev. Biol. 64, 57-71 (2004).
6. Tonon G, Wong KK, Maulik G et al.: High-resolution genomic profiles of human lung cancer. Proc. Natl Acad. Sci. USA 102(27), 9625-9630 (2005).
7. Li H, Luan Y: Kernel Cox regression models for linking gene expression profiles to censored survival data. Pac. Symp. Biocomput., 65-76 (2003).
8. Danesi R, de Braud F, Fogli S et al.: Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol. Rev. 55, 57-103 (2003).
9. Bild AH, Yao G, Chang JT et al.: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074), 353-357 (2005).
10. Sweet-Cordero A, Mukherjee S, Subramanian A et al.: An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genet. 37, 48-55 (2005).
11. Muller-Tidow C, Metzger R, Kugler K et al.: Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61(2), 647-653 (2001).
12. Powell CA, Spira A, Derti A et al.: Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am. J. Respir. Cell. Mol. Biol. 29(2), 157-162 (2003).
13. Fukumoto Si, Yamauchi N, Moriguchi H et al.: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 11 (5), 1776-1785 (2005).
14. Ji P, Diederichs S, Wang W et al.: MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22(39), 8031-8041 (2003).
15. Muller-Tidow C, Diederichs S,Thomas M, Serve H: Genome-wide screening for prognosis-predicting genes in early-stage non-small cell lung cancer. Lung Cancer 45(Suppl. 2), 145-150 (2005).
16. Beer DG, Kardia SLR, Huang CC et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8(8), 816-824 (2002).
17. Rom WN, Tchou-Wong KM: Functional genomics in lung cancer and biomarker detection. Am. J. Respir. Cell Mol. Biol. 29(2), 153-156. (2003).
18. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
19. Tomida S, Koshikawa K. Yatabe Y et al.: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 23(31), 5360-5370(2004).
20. De Luca A, Pignata S, Casamassimi A et al.: Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription PCR assay. Clin. Cancer Res. 6(4), 1439-1444 (2000).
21. Mao L: Recent advances in the molecular diagnosis of lung cancer. Oncogene 21(45), 6960-6969(2002).
22. Kopreski MS, Benko FA, Gocke CD: Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann. NY Acad. Sci. 945, 172-178 (2001).
23. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
24. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1(5), 511-529 (1983).
25. Dowsett M, Bartlett J, Ellis IO et al.: Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199(4), 418-423 (2003).
26. Bartlett JMS: Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. Am. J. Pharmacogenomics 5(5), 303-315 (2005).
27. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341-354 (2005).
28. Wakeling AE, Guy SP, Woodburn JR et al.: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62(20), 5749-5754 (2002).
29. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), 9-15 (2001).
30. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64(24), 8919-8923 (2004).
31. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
32. Tomizawa Y, Iijima H, Sunaga N et al.: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin. Cancer Res. 11 (19 Pt 1), 6816-6822 (2005).
33. Jain A, Tindell CA, Laux I et al.: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc. Natl Acad. Sci. USA 102(33), 11858-11863 (2005).
34. Tsai C-A, Wang S-J, Chen D-T, Chen JJ: Sample size for gene expression microarray experiments. Bioinformatics 21, 1502-1508 (2005).
35. Li SS, Bigler J, Lampe JW, Potter JD, Feng Z: Controlling FDR and sample size determination for microarrays. Stat. Med. 24, 2267-2280 (2005).
36. Ornstein DK, Gillespie JW, Paweletz CP et al.: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoreris 21(11), 2235-2242 (2000).
37. Repsilber D, Ziegler A: Two-color microarray experiments. Technology and sources of variance. Methods Inf. Med. 44 (3), 400-404 (2005).
38. Neuschafer D, Budach W, Wanke C, Chibout SD: Evanescent resonator chips: a universal platform with superior sensitivity for fluorescence-based microarrays. Biosens. Bioelectron. 18(4), 489-497 (2003).
39. Hoffmann R, Seidl T, Dugas M: Profound effect of normalization on detection of differentially expressed genes in oligonucleotide microarray data analysis. Genome Biol. 3(7), RESEARCH0033 (2002).
40. Irizarry RA, Hobbs B, Collin F et al.: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistic 4(2), 249-264 (2003).
41. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2), 185-193 (2003).
42. Yang P, Sun Z, Aubry MC et al.: Study design considerations in clinical outcome research of lung cancer using microarray analysis. Lung Cancer 46 (2), 215-226 (2004).
43. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95(25), 14863-14868 (1998).
44. Alaiya AA, Franzen B, Hagman A et al.: Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns. Int. J. Cancer 86(5), 731-736 (2000).
45. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M: Correspondence analysis applied to microarray data. Proc. Natl Acad. Sci. USA 98(19), 10781-10786 (2001).
46. Furey T, Cristianini N, Duffy N, Bednarski D, Schummer M, Haussler D: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16(10), 906-914 (2000).
47. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl Acad. Sci. USA 99 (10), 6567-72 (2002).
48. Musumarra G, Barresi V, Condorelli DF, Fortuna CG, Scire S: Genome-based identification of diagnostic molecular markers for human lung carcinomas by PLS-DA. Comput. Biol. Chem. 29(3, 83-195 (2005).
49. Culhane AC, Perrière G, Considine EC, Cotter TG, Higgins DG: Between-group analysis of microarray data. Bioinformatics 18(12), 1600-1608 (2002).
50. Suzuki R, Shimodeira H: An application of multiscale bootstrap resampling to hierarchical clustering of microarray data: how accurate are these clusters? In Genome Informatics 2004 (2004).
51. Granville CA, Dennis PA: An overview of lung cancer genomics and proteomics. Am. J. Respir. Cell Mol. Biol. 32(3), 169-176 (2005).
52. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA: Non-small cell lung cancer molecular signatures recapitulate lung developmental pathways. Am. J. Pathol. 163(5), 1949-1960 (2003).
53. Garber ME, Troyanskaya OG, Schluens K et al.: Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98(24), 13784-13789 (2001).
54. Bhattacharjee A, Richards WG, Staunton J et al.: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98 (24), 13790-13795 (2001).
55. Talbot SG, Estilo C, Maghami E et al.: Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res. 65(8), 3063-3071 (2005).
56. Virtanen C, Ishikawa, Y, Honjoh D et al.: Integrated classification of lung tumors and cell lines by expression profiling. Proc. Natl Acad. Sci. USA 99(19), 12357-12362 (2002).
57. Creighton C, Hanash S, Beer D: Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas. FEBS Lett. 540(1-3), 167-170 (2003).
58. Wang H, Zhang Z, Li R et al.: Overexpression of S100A2 protein as a prognostic marker for patients with stage I non-small cell lung cancer. Int. J. Cancer 116(2), 285-290 (2005).
59. Nguyen DV, Rocke DM: Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics 18(9), 1216-1226 (2002).
60. Yee YJ, Mangasarian OL, Wolberg WH: Survival-time of breast cancer patients. Tech. rep., Department of Computer Science & Information Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan (2001).
61. Ntzani EE, Ioannidis JPA: Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362(9394), 1439-1444 (2003).
62. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21(2), 171-178 (2005).
63. Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365(9458), 488-492 (2005).
64. Carr KM, Rosenblatt K, Petricoin EF, Liotta LA: Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum. Genomics 1(2), 134-140 (2004).
65. Irizarry RA, Warren D, Spencer F et al.: Multiple-laboratory comparison of microarray platforms. Nature Methods 2(5), 345-350 (2005).